As former leader and founder Nessan Bermingham walks away from Intellia Therapuetics, it has named John Leonard as its new president and chief. 

According to Fierce Biotech, Leonard will take up the position in the New Year, having previously worked across numerous infectious disease and cancer programs. 

“After nearly four years of building Intellia and this exceptional team, the company is now posed to begin development of CRISPR/Cas9-based therapies,” said Bermingham. 

“At this stage, Intellia requires a CEO with a track record of successful drug development. John was the first to join me in starting Intellia, and was an ideal partner because of his unmatched R&D expertise and biopharmaceutical leadership experience. As I return to my roots in biotech venture capital, I am confident that Intellia, the science and our employees are in great hands.”

The biotech went on to announce that it would be promoting an R&D lead, they said in a statement, “In recognition of the company’s growth and expanding pipeline, the board of directors and Dr. Bermingham agreed that Dr. Leonard should lead the company as it progresses toward clinical development, given his experience in successfully developing biopharmaceutical products and leading large scientific organisations.”

Nessan Bermingham has revealed that he will be returning to the venture capital industry in the meantime.